



## COVID AND THE EMERGENCE OF THE NEW STRAINS: A BRIEF REVIEW

Shruti Shringi, \*Pallavi Sharma, Neha Chauhan, and Shweta Gupta

Department of Microbiology, University of Kota, Kota, India

**Corresponding author: Pallavi Sharma**

Email: drsharmapallavi10@gmail.com

---

**Article History:** Received: 03.05.2023      Revised: 21.05.2023      Accepted: 24.05.2023

---

### Abstract

COVID-19 is a respiration-related ailment brought on through SARS-CoV-2 and was once recognized in China's Wuhan city. More than 223 nations are affected by the ailment worldwide. The new variants of the COVID-19 virus are inflicting problems, from average to life-threatening pneumonia and acute respiratory distress syndrome (ARDS). Presently, there are a hundred and seventy vaccine candidates, out of which 10 have been permitted by the WHO for vaccination, such as Ad26.COV2. S, Pfizer/BioNTech, COVISHIELD, Covovax, Moderna, Co-vivac, and some different vaccines to fight the deadly SARS-CoV-2 infection. From all these vaccines, Pfizer/BioNTech and Moderna are showing the best efficacy towards COVID-19. These vaccines are pretty environment friendly towards COVID-19 disease, however their potentiality in opposition to new variations stays a question. COVID-19 vaccines are relatively fine at preventing severe illnesses, hospitalizations, and death. The antibodies elicited by way of beforehand contamination or vaccination are the key for viable safety in opposition to SARS-CoV-2. The trouble has been exacerbated by new statistics from Africa on the origins of the novel contagious SARS-CoV-2 strains. These new lines occur due to unique mutations in spike protein, which adjust SARS-CoV-2 transmission and infection capabilities, limiting the efficacy of the covid-19 vaccination. Hence, there is a need to find a plausible vaccine against it.

**Key words:** Covid, Virulence, Contagious, SARS-CoV-2, Variants, Strains.


---

## Introduction

The earliest human coronaviruses, OC43 and 229E, had been discovered in the 1960s, followed by SARS – COV in 2003, HCoV-NL63 in 2004, HKU1 in 2005, MERS-COV in 2012, and sooner or later the SARS-CoV-2 outbreak in December 2019 [V.M.Corman et al., 2018, A.B. Parikhani et al.,2021]. In early December 2019, in China, in the town of Wuhan, some sufferers had been recognized with pneumonia. Later on, it was once confirmed with the aid of metagenomics evaluation the usage of next-generation sequencing of the sample of bronchoalveolar lavage of pneumonia sufferers and its binding capability with ACE2 receptor led the researcher to dub it as nCoV-2019 on 31 December 2019 at Wuhan Institute of Virology [C.Del Rio et al.,2020,P.Wu,Hao et al., 2020].However, due to the lower availability of ACE2, numerous coreceptors, choice receptors, and attachment factors, consisting of heparan sulphate, neutrophils, sialic acids, GRP78, and CD147 (BSG), have been discovered to resource virus invasion in the respiratory system[A.B. Parikhani et al.,2021,C.Ganier et al.,2020].Based on phylogeny, taxonomy, and demonstrated experience, nCoV-2019 was named as SARS-CoV-2 via the Corona-viridea Study Group (CSG)[A.E.Gorbalenya et al.,2020]. On 12 March 2020, the World Health Organization (WHO) declared this sickness a pandemic, as it unfold to different countries swiftly through human-to-human transmission [V.M.Corman et al.,2018,A.B.Parikhani et al.,2021].There is a subject on its starting place that from which animals it originated and whether it can be transmitted from animals. The SARS-CoV-2 genetic sequence is 79.5% similar to SARS-CoV and 96.2% homologous to a bat coronavirus (HKU9-1) [C.Del Rio et al.,2020]. Human coronaviruses are classified as contributors of the Noroviruses order, which includes the households Coronaviridae,

One of the major causes of mortality in the Arteriviridae, and Roniviridae, as illustrated in Figure 1. Coronaviridae is in addition subdivided into the Coronavirinae and Torovirinae families. Alpha, Beta, Gamma, and Delta are the four agencies that make up the Coronavirinae subfamily. Mammals are contaminated via Alpha and Beta, while birds are infected by way of Gamma and Delta [A.B. Parikhani et al.,2021]. When it comes to phylogenetic classification, human coronaviruses are labeled as Baltimore classification IV viruses considering the fact that they are enveloped and incorporate positive-sense single-strand RNA. Till now, seven species of coronaviruses are known; these are HCoV-NL63, HCoV-229E, HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2 from which the first two belongs to the Alpha genus whilst others to Beta genus. The  $\beta$ -coronaviruses can infect animals and human beings with asymptomatic infections and lead to an outbreak as these are single-stranded RNA-enveloped viruses [X. Xu, P.Chen et al.,2020].Bats appear to be the intermediary host between human and bat transmission chains [N.R. Faria, et al.,2021,V.Thakur et al., 2021].The phylogenetic tree of the SARS-CoV-2 virus shows that it is a recombinant virus, with about 89 percent homology with the SARS bat virus, SCCoVZC21 strain (NCBI accession wide variety MG772934), and bat-SL-CoVZC45 (NCBI accession quantity MG772933), and about 92–96 percent homology with RaTG13, the bat coronavirus, in accordance to a latest find out about[A.B. Parikhani et al.,2021,C. Li et al.,2020].The coronaviruses are polyhedral spherical viruses with a diameter of eighty to 160 nm and a large genome dimension of about 27.6–31.6 with trimers of spike proteins as projections which are visible on an electron microscope [P.S. Masters, 2006, S. Navas-Martin et al.,2004].The membrane glycoprotein (M) protects the

envelope by means of strengthening the membrane and attaches



itself to the nucleocapsid which binds to the RNA genome, and it consists of a coat protein (E) which helps in pathogenesis, assembly, and launch of the virus [P.S.Masters 2006, Y.Chen et al., 2004].Coronavirus has a single-stranded positive-sense RNA genome with many open reading frames, a cap at the 5' terminus, and a poly(A) tail at the 3'

terminus. Replicase, S-EM-N glycoproteins, and other minor ORFs representing subproteins that are disbursed in the course of structural genes make up the steady association of genes from the 5'

to 3' end [R.A. Khailany et al.,2020, A.A. T.Naqvi et al., 2020].As compared to SARS-CoV, it has been found that SARS-CoV-2 has extra potential to infect and replicate inside alveolar tissues with milder signs causing pneumonia [Y.Chen et al., 2020, H.Chu et al.,2020].It can attach to the ACE-2 (angiotensin-converting enzyme two receptor), and the on April 10, 2022, with 6 million deaths suggested to the WHO. A total of 11.6 billion vaccine doses have been delivered as of April 2022 [WHO, SARS-CoV-2 2021]. COVID-19 situations diminished by means of 24 percent and mortality with the aid of 18% from 14 March 2022 to 10 April 2022 in four consecutive weeks. 7.2 million new cases and over 22,336 new deaths were suggested in this week. The incidence of weekly cases reduced in all regions, with the Americas region reporting the easiest make bigger (-4 percent), observed by South-East Asia (-8 percent), Europe (-26 percent), the Eastern Mediterranean (-4 percent), and the Western Pacific (-38 percent), and Africa (-17 percent). The loss of life charge also lowered this week in Americas (-19%),

Western Pacific (-26%), South-East Asia (-15%), Eastern Mediterranean (-18%), and European Regions (-16%), all of them said a drop in the variety of deaths [WHO, SARS-CoV2 2021].

The SARS-CoV-2 transmission is influenced by way of a range of abiotic factors such as climate, temperature, humidity, wind speed, air, and water quality, solid surfaces/interfaces, and frozen food, and biotic elements like age, sex, gender, blood type, population density, and behavioral characteristics. Based on transmission, persistence, and infectivity, there are a number of therapeutics tactics which have been employed to combat against SARS-CoV2 [S.Kumar, R Singh et al.,2021].There are more than a few therapeutic procedures

spike protein will mediate membrane fusion and viral entry [A.B. Parikhani et al.,2021,G.Zhou and Q. Zhao et al.,2020].The sickness is unfold especially through respiratory droplets such as coughing and sneezing when people are in proximity [A.B. Parikhani et al.,2021,C. Huang et al.,2020, WHO, SARS-CoV-2 2021].COVID-19-confirmed instances totalled 469 million which have been employed to fight against SARS-CoV-2 infection. Previously, some manageable antimalarial tablets like hydroxy chloroquine and azithromycin, ant filarial drug ivermectin, and antiviral capsules have been tested by way of many research agencies worldwide for their viable impact against the COVID-19, but they did now not show tremendous response on COVID-19 patients. The combination of these pills such as hydroxychloroquine and ivermectin have been recognized to act through developing the acidic circumstance in cells and inhibiting the importin (IMPα/b1)-mediated viral import [A.J. Siddiqui et al.,2021]. Recently, mesenchymal stem cells (MSCs) have been brought as a conceivable therapeutic approach for treating SARS-CoV-2 [A. Akbari et al.,2020]. In silico study showed an inhibitory impact of ilimaquinone (marine sponge metabolite) in opposition to this new virus [M.Surti et al.,2020]. Some plant-derived natural products are additionally below investigation to increase a drug against this life-threatening virus. Besides all therapeutic approaches, vaccine improvement is the most promising remedy to manipulate COVID-19 infection. There have been about 200 candidates underneath the medical investigation, 69 candidates in 3rd clinical trial, sixty-nine candidates in 2nd clinical trial, and 48 are in segment 1 trial. There are 10 vaccine candidates permitted with the aid of the WHO (Table 1) for vaccination [WHO, SARSCoV-2 2021].

globally, however as this virus is mutating quickly, it is growing a havoc each time.

The severity of infections has grown due to a variety of SARS-CoV-2 mutations. The new and rising respiratory virus threats advisory crew (NERVTAG) in the United Kingdom published a file containing the findings of several preliminary analyses of B.1.1.7 [T.Burki 2021]. In England, a tremendously transmissible variant with eight mutations on the S protein was detected, out of which three have been foremost antigenic determinants for vaccine licensed there [T.Burki 2021]. In 2021, NERVTAG knowledgeable that B.1.1.7 is greater infectious and extreme than the mother or father virus. P.1 is some other tremendously infectious variant suggested in Brazil which led to collapsing of health branch in the mid-2020 [T. Burki 2021]. In 2020, a new variant B.1.351 was once observed in South Africa, and Moderna claimed that its vaccine is wonderful against each B.1.1.7 and B.1.351 variations based totally on in vitro research. The employer Pfizer also claimed primarily based on laboratory studies that their vaccine works in opposition to B.1.1.7 variant, however there is no proof as these studies have been no longer peer-reviewed [T.Burki 2021]. With the emergence of new variants, the severity of disease will increase, and vaccines will not work against the new variants. Therefore, for stopping disorder transmission due to these new variants, we want to follow the WHO encouraged control measure and develop effective vaccine. The world has been terrified with the aid of the SARS-CoV-2 outbreak. There is a need to recognize the pathophysiology of the virus, locate a

solution, and in the in the meantime battle towards the COVID-19 pandemic. This review tries to supply current Information concerning COVID-19 editions to better recognize this altering novel virus and its relevance. The WHO acquired a lot of public health problems due to the SARS-CoV-2 new editions. To fight COVID-19 infection, viral genomic sequences have been developed, and over one million SARS-CoV-2 sequences have been submitted to GISAID (<https://www.cdc.gov/coronavirus/2019/variants/variant>). The on hand genomic records should be used in monitoring the outbreaks, international spread, and evolution of SARS-CoV-2. The evolution of SARS-CoV-2 has persevered and emerged as new versions that have spread all over considering its beginning,

Most viral mutations are the ability of a virus to infect, replicate, and escape a host Immunity and infection; however, certain mutations can give viral strains a competitive advantage empowered by natural selection become dominant. Many mutations observed in SARS-CoV2 variants are FGE or altering the N-terminal domain of the S protein Three-dimensional structure of S protein. but also, these changes can affect infection A virus, but it can also allow him to better escape it Immune response, e.g., by neutralizing antibodies induced by either B. vaccine administration or natural infection. The SARS- Co-V 2 contagion has shifted multitudinous times, with estimates suggesting that circulating lineages acquire nucleotide mutations at rates of around one to two mutations per month [Duchene S, Featherstone L, et al.2020] The current system of relating variants relies on the use of genomic testing similar as whole genome sequencing, partial S gene sequencing, or assays grounded on nucleic acid

modification. [Ecdc.europa.eu 2021] aspects of different variants that utmost people witness, still, is the clinical symptoms they induce. Certain variants (e. g. alpha, delta) induce a lesser threat of severe complaint and death, [Cdc.gov. 2021] while others (e.g., omicron) are more likely to induce milder symptom. [Imperial.ac.uk 2021, Gov.uk.2021] also, individual symptoms can differ between variants. For illustration, the gamma variant is associated inflicting anosmia and dysgeusia, [Luna-Muschi A, Borges et al.2022] which is lower generally seen in omicron infections. Moving forward, the clinical themes and symptoms associated with arising variants should be illustrated fleetly so that the public and healthcare professionals can fleetly identify possible cases of covid- 19. WHO has tracked and covered SARS- Co-V- 2 variants since the covid- 19 epidemic began to identify variants of concern? As of 25 January 2022, WHO reported five variants of concern, two variants of interest, and three variants under monitoring [Who.int. tracking SARS -CoV-2 Variant 2022] Then, we report studies that compare SARS- Co-V- 2 variants to the primary contagion strain. The primary strain is the strain of the contagion that first surfaced in Wuhan, China at the end of 2019 and spread around the world in the first surge of infections, which is frequently also appertained to as the Wuhan Hu- 1, B.1, or wildtype strain.

## Variants of Concern

### *Alpha variant B .1.1.7*

The alpha SARS-CoV-2 variant of the B.1.1.7 lineage was first documented in the UK in September 2020 and categorized as a variant of subject on 18 December 2020. [Who.int. tracking SARS -CoV-2 Variant 2022, Gov.uk. investigation of novel SARS-CoV-2 2021]. This variant carries S protein mutations that have doable biological effects. Firstly, the S

protein residue 501, a key contact residue within the RBD, varieties a portion of the binding loop in the contact region of the ACE2 receptor, forms a hydrogen bond with the Y41 residue of the ACE2 receptor, and stabilizes the ACE2 K353 residue.[Lan J, Ge J et al.,2020, Wang Y et al.,2020 Yi C et al.,2020] The alpha variant has an N501Y mutation, which will increase the binding affinity of the RBD to the ACE2 receptor.[Starr TN et al.,2020] Next, the P681H mutation contained within the alpha variant is placed at once adjoining to the 682-685 furin cleavage site, at the interface of the S1 and S2 domains.[Huang Y, Yang C et al.,2020] The S1/S2 furin cleavage website prompts entry into respiratory epithelial cells and partly determines the transmissibility of the virus,[Hoffmann M, Kleine-Weber H et al.,2020, Peacock TP, Goldhill DH,et al.,2020,Zhu Y, Feng F, et al., 2020] while the P681H mutation makes the furin cleavage site much less acidic, that means it is extra effectively recognized and cleaved.[Scudellari M. 2021, Wang Q, Qiu Y, et al.,2019] Alpha additionally contains a D614G mutation, placed within the S1/S2 furin cleavage site, which will increase SARS-CoV-2 binding affinity to the ACE2 receptor and increases infectivity.[Yurkovetskiy L, Wang X, et al., 2020] Other mutations inside the alpha variant decorate the ability of the virus to break out antibody detection, such as the two amino acid deletion at web sites 69-70 in the N-terminal area of the S protein,[McCarthy KR, Rennick LJ, Nambulli S. 2021, Kemp SA, Collier DA 2020 ]while different mutations exhibit confined or no effects.[Gamage AM, Tan KS, et al., 2020] In February 2021, viruses of the B.1.1.7 lineage with the introduced S protein mutation E484K had been identified, which could have threatened vaccine effectiveness owing to the mutation conferring an accelerated resistance to neutralizing vaccine elicited and monoclonal anti- bodies.[Collier DA,

De Marco A, et al.,2021] This mutation had restricted effects, however, and variations containing it failed to dominate. Epidemiological studies have explored the alpha variant, with a case-control study of 27 633 respiratory samples originating from 20 fundamental care centres in Madrid, Spain, discovering that the probability of admission to an intensive care unit used to be twice as high in sufferers infected with the alpha variant compared with those contaminated with the predominant strain.[Martinez-Garcia L, Espinel MA, et al.,2021] Furthermore, this variant became the dominant strain inside 4 months, and led to an increase in sickness burden as a result.[ Martinez-Garcia L, Espinel MA, et al.,2021] Meanwhile in Cannes, France, infection with the alpha variant was once related with a 3.8-fold greater risk of switch to intensive care or demise in contrast with the fundamental strain, as decided via a retrospective cohort find out about of 158 sufferers with covid- 19.[Vassallo M, Manni S, et al., 2021] A massive retrospective cohort find out about such as a total of 476 973 contributors discovered that, during the third covid-19 wave in Canada, where 91% of infections were brought about by means of the alpha variant, the chance of both clinic admission (adjusted odds ratio 1.57) and loss of life (1.52) was once higher than main strain infections.[McAlister FA, Nabipoor M, et al., 2021] Overall, the alpha variant used to be about 50-70% more transmissible and was once associated with a 30-60% elevated hazard of health center admission and death compared with the foremost strain.[Davies NG, Abbott S, et al.,2021, Leung K, Shum MH et al.,2021, Zhao S, Lou J, et al., 2021, Gov.uk. NERVTAG paper on covid-19 variant of concern,2021, Challen R, Brooks-Pollock E, et al., 2021, Paredes MI, Lunn SM et al., 2022] The alpha variant was found to have a minimal impact on the effectiveness of modern

vaccines,[Wang P, Nair MS et al.,2021, Wu K, Werner AP et al.,2021] while the risk of reinfection remained similar for this variant as with previous ones.[Gallais F, Gantner P, et al.,2021] On 3 September 2021, the European Centre for Disease Prevention and Control (ECDC) reclassified the alpha, and the alpha E484K mutation versions from a variant of concern to a de-escalated variant.[Ecdc, Europea ,eu SARS-CoV-2 Variants of concern 2022].

### **Beta variant B. 1. 351**

The beta SARS-CoV-2 variant, of the B.1.351 lineage, was first documented in South Africa in May 2020. [Who.int Tracking SARS-CoV-2 Variants.2022] This variant contains five S protein mutations of interest: N501Y, E484K, D614G, K417N, and A701V. Like the alpha variant, the beta variant carries the mutations N501Y, E484K, and D614G, which increase ACE2 receptor binding affinity,[Starr TN, Greaney AJ, et al 2020, Yurkovetskiy L, Wang X, et al., 2020] extend virulence,[Gu H, Chen Q, et al.,2020] and enhance resistance to neutralising antibodies.[Collier DA, De Marco A, et al.,2021, Plante JA, Liu Y, et al.,2021] The K417 residue of the SARS-CoV-2 S protein interacts with the D30 residue of the ACE2 receptor, forming a salt bridge throughout the central contact region,[Lan J, Ge J, et al.,2020, Wang Y, Liu M, et al.,2020]though the K417N mutation appears to have a restrained have an effect on on ACE2 receptor binding.[Starr TN, Greaney AJ et al .,2020] The A701V mutation is positioned shut to the furin cleavage website however has a minimal effect on transmissibility or antibody resistance.[Wang P, Nair MS, et al.,2021] In a genomic and epidemiological study, researchers concluded that the beta SARS-CoV-2 variant had a selective gain over previous variants from its increased transmissibility and immune escape abilities,[ .[Pearson

CA, Russell TW et al.,2021, Wibmer CK, Ayes F ,et al.,2021] whereas the E484K/N501K mutations more suitable the binding affinity of the beta variant and, hence, multiplied its transmissibility.[Sinha S, Tam B, et al.,2021] A retrospective cohort study of 22 68 participants found that infection with the beta variant was associated with an extended danger of hospital admission compared with an contamination with a non-variant of concern (hazard ratio 2.30).[Paredes MI, Lunn SM et al.,2022] Overall, the beta variant is about 25-50% extra transmissible, is associated with a viable enlarge in hazard of hospital mortality, and has superior resistance to anti- body neutralisation in contrast with preceding variants.[Pearson CA, Russell TW et al.,2021, Wibmer CK, Ayes F ,et al.,2021, Campbell F, Archer B, et al.,2021]

### ***Gamma variant P.1***

The gamma variant is of the P.1 lineage and was first reported in November 2020 from visitors returning to Japan from Brazil, and was once later found in Brazil.[Who.int.Tracking SARSCoV-2 Variants2022, Ecdc.europa.eu Risk assessment: SARS-CoV-2, 2021] This variant includes the following S protein mutations of interest: K417T, E484K, N501Y, D614G, and H655Y.[Ecdc,europa.eu SARS-CoV-2 Variants of concern 2022] As mentioned, the N501Y and D614G mutations amplify each ACE2 receptor binding affinity and infectivity of the virus.[Starr TN, Greaney AJ et al.,2020, Yurkovetskiy L, Wang X, et al., 2020] The N501Y, K417N/T, and E484K mutation trinity, meanwhile, is shared through both gamma and beta variants, and is associated with stronger infectivity and lethality in contrast with the N501Y mutation alone, possibly from tighter binding of the S protein to the ACE2 receptor due to elevated electrostatic contribution.[Khan A, Zia T, et al., 2021

]The gamma variant additionally includes the H655Y mutation, which was once observed to grant enhanced viral escape skills from a couple of human monoclonal antibodies in vitro.[Baum A, Fulton BO, et al.,2020] The gamma variant is associated with heightened transmissibility,[Sinha S, Tam B, et al., 2021, Campbell F, Archer B, et al.,2021, Curran J, Dol J, et al.,2021] with one study concluding that it possesses a 1.7-fold to 2.4-fold expanded transmissibility in contrast with preceding variants.[de Faria E, Guedes AR, et al.,2021] Additionally, the wave of infections brought about by the gamma variant in Brazil was associated with a 13% amplify in dying fee in contrast with the previous wave, suggesting the increased virulence held through the gamma variant than through previous viral strains.[Freitas ARR, Beckedorff OA, et al., 2021] A surveillance study from seven European countries concluded that the gamma variant used to be associated with a higher risk of admission to medical institution (adjusted odds ratio 2.6) and intensive care (2.2) when compared with instances of non-variants of concern.[Funk T, Pharris A, et al.,2020] In Manaus, Brazil, the resurgence of covid-19, despite high seroprevalence, recommended that the gamma variant had a moderate resistance to neutralising antibodies,[Sabino EC, Buss LF et al ., 2021] however, the variant has been proven to be notably less resistant to neutralising antibodies than other variants, including the beta variant.[Dejnirattisai W, Zhou D, et al., 2021]

### ***Delta variant B. 1. 617.2***

The delta variant, from the B.1.617.2 lineage, used to be first documented in India in October 2020 and was once classified as a variant of situation on eleven May 2021. [Who.int. Tracking SARS-CoV-2 variants.2021] The S protein



mutations of interest P681R and D614G are additionally placed in the delta variant[Ecdc.europa.eu.SARS-CoV-2 2022] and similarly have an effect on its ACE2 receptor binding affinity and transmissibility.[Plantae JA,Liu Y, et al., 2021, Korber B, Fischer WM, et al.,2016, Volz E, Hill V, et al., 2016]Unlike the E484K mutation seen in preceding variants, the delta variant incorporates the E484Q mutation that, along with a L452R mutation also positioned inside the RBD, motives notably higher affinity for the ACE2 receptor than the main strain or the E484K mutation alone.[Augusto G, Mohsen MO et al.,2021] The L452Rn mutation alone consequences in larger RBD-ACE2 receptor binding affinity and more advantageous break out from neutralising antibodies.[Tchesnokova V, Kulakesara H, et al., 2021, Li Q, Wu J, et al., 2020 ]Lastly, the delta variant contains the T478K mutation, located on the interface between the S protein and the ACE2 receptor when bound, which increases the electrostatic potential of the S protein and enhances binding affinity.[Di Giacomo S, Mercatelli D, et al., 2021] The delta variant shortly grew to become the dominant variant in the UK, [Torjesen I. Covid- 19 delta variant, 2021] US, [Reuters.com.Delta COVID variant 2021] Europe, and around the world.[Euro.who.int. SARS-Cov-2 delta variant,2021] The mutations existing in the delta variant enhanced the transmissibility of the virus as an end result of improved binding affinity to the ACE2 receptor.[Sinha S, Tam B, et al., 2021] The replica range of the delta variant is estimated to be 97% higher than that of non-variants of concern or non-variants of interest, and about three times that of the alpha, beta, and gamma

variants.[Campbell F, Archer B, et al., 2021] This extended reproductivity highlights the delta variant's competitive advantage over formerly ones and how it hastily became the dominant stress globally. The speedy replication fee of delta probably contributes to its elevated transmissibility compared with the alpha, beta, and gamma variants. In a cohort find out about consisting of [Chung H, He S, et al., 2021]infections, the delta variant should be detected by way of polymerase chain reaction within the first 4 days from exposure, whereas non-delta covid-19 infections should be detected after only six days.[Li B, Deng A, et al.,2021] Furthermore, humans contaminated with the delta variant have been observed to have drastically greater viral loads than people infected with different strains,[ Li B, Deng A, et al.,2021] including the beta variant.[Teyssou E, Delagreverie H, et al.,2021]The delta variant is also idea to better get away neutralization, with the frequency of post-vaccination infections a great deal higher for the delta variant than infections with the primary stress in India,[Kumar A , Asghar A, et al., 2021] and blood serum samples from folks who had acquired one dose of a covid-19 vaccine displaying minimal neutralization of the delta variant.[Planas D, Veyer D, et al., 2021]The delta variant is also related with an increased disease severity. In Scotland, contamination with the delta variant was related with an elevated risk of hospital admission (hazard ratio 1.85) compared with contamination with the alpha variant.[Sheikh A, McMenamin J, et al., 2021] Compared with infections involving non-variants of concern, North American retrospective cohort studies confirmed that contamination with the delta variant was related with a 1084 or

hazard ratio of 2.28 (95% confidence interval 1.56-3.34) a hundred extended risk of hospital admission, a 234% expanded risk for admission to intensive care, and a 132% expanded risk of death.[Fisman DN, Tuite AR, et al., 2021] Lastly, in a go sectional find out about of 6238 humans infected with the delta variant and 3262 infected with the important pressure in India, researchers discovered that the chance of demise used to be around 1.8 instances greater for delta infections, while the delta variant also infected and brought about signs in a greater percentage of youthful people (age 0-19 years) than did the essential strain.[ Kumar A , Asghar A, et al., 2021]

#### **Omicron variant B.1.1.529**

The omicron variant is of the B.1.1.529 lineage and was first determined in November 2021 in South Africa and Botswana earlier than being detected in multiple countries and labeled as a variant of challenge on 26 November 2021. [Who.int. Tracking SARS-CoV-2 Variants.2022] This variant consists of over 30 S protein mutations, [Li R, Tian J et al., 2020, Ecdc.europa.eu. SARS-CoV-2 variants of concern 2022] of which have been previously identified, inclusive of K417N, T478K, E484A, D614G, H655Y, P681H, and N501Y.[Cameroni E , Saliba C, et al., 2021] Fifteen omicron mutations are contained within the RBD,[Cao Y, Wang J, et al., 2021] providing the variant with a substantially more advantageous binding affinity to the ACE2 receptor.[Cameroni E, Saliba C, et al., 2021, Shah M, Woo HG, et al., 2021] In addition, more than a few single mutations in the RBD of the omicron variant impair the effectiveness of neutralizing antibodies, together with K417N, N440K, G446S, E484A, Q493K, G496S, G339D, S371L, and S375F.[Cao Y, Wang J, et al., 2021]The emergence of omicron has been

accompanied by using a surge of infections worldwide. Early statistics from South Africa have indicated that the proportion of covid-19 infections prompted by means of the omicron variant rose from 3% in early October 2021 to 98% by early December 2021. [Wolter N, Jassat W, et al., 2021] In late December 2021, meanwhile, the doubling time for the range of omicron infections was between two and three in the UK, US, and an awful lot of Europe, [Gov.uk. Omicron daily overview 2021, Who.int. Enhancing readiness for omicron 2021] highlighting the transmissibility of this variant. The mutations in the omicron variant that beautify its binding affinity [Cameroni E, Saliba C, et al., 2021, Shah M, Woo HG, 2021] and potential to escape neutralizing antibodies [Cao Y, Wang J, et al.,2021] likely drove its rapid spread, as did its quickly replication rate, which is round 70 times faster than the delta and principal strains. [Med.hku.hk. HKUMed Finds omicron 2021] The reinfection rate of the omicron variant has additionally been determined to be greater than ten instances higher than that of preceding versions in studies from Scotland[Sheikh A, Kerr S, et al. 2021] and South Africa.[Pulliam JRC, van Schalkwyk C, et al ., 2022] The omicron variant has significant however incomplete escape capabilities from naturally received and vaccine induced immunity.[Cele S, Jackson L, et al., 2021] one hundred forty four Compared with the delta variant, the omicron variant desires round a 10-fold increased antibody titre to be neutralized, after vaccination with both the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) vaccines.[Meng B, IATM F, et al., 2021]Indeed, blood serum from persons who had received two doses of the BNT162b2 vaccine showed extra than a 25-fold discount in neutralizing antibody titres in opposition to the omicron variant compared with the main strain.[Pfizer.com. Pfizer and BioNTech

provide update on omicron variant 2021] T phone responses to the omicron variant could continue to be intact, however. Data from one preprint study indicated that 70-80% of the T telephone response concentrated on the S protein was once maintained in those individuals vaccinated or with previous infection, while the magnitude of T cells cross reacting with the omicron variant used to be comparable to that of both delta and beta variants.[Keeton R, Tincho MB, et al.,2021] Furthermore, data from Pfizer BioNTech published that 80% of the epitopes in the omicron variant S protein that are recognized by using CD8 T cells were now not affected through the variant's mutations, after two doses of the vaccine.[ Pfizer.com. Pfizer and BioNTech provide update on omicron variant 2021] T- cell responses precipitated from vaccination or prior infection could, therefore, supply some safety from severe disease. Recent actual world proof has implied that omicron contamination is milder in severity than previous variants. In an early South African analysis, the chance of hospital admission (adjusted odds ratio 0.2) was lower for omicron infections than for non-omicron infections, [Wolter N, Jassat W, et al.,2021] whilst omicron contaminated folks had a lower chance of severe disease than delta contaminated individuals (0.3)., [Wolter N, Jassat W, et al.,2021] In December 2021 in England, omicron infections have been discovered to result in a substantially reduced threat of clinic admission or presentation for emergency care than delta infections.[Imperial.ac.uk. Report 50-2021, Gov.uk. SARACoV-2- 2021] The decreased disorder severity inflicted via the omicron variant may want to be due to its decreased capacity for replication in lung tissue, which used to be located to be more than 10 instances much less in lung tissue than the delta variant. [Med.hku.hk. HKUMed finds omicron SARS-CoV-22021] Concordantly, the S protein of the

omicron variant is less efficient at cleaving the ACE2 receptor and coming into cells of lung organoids, [Meng B, IATM F, et al., 2021] and is additionally less capable to cause fusion between lung cells than the S protein of the delta variant, [ Meng B, IATM F, et al., 2021] which is often observed in severe covid19. The discount in replication inside the lungs, and the protection of T phone responses probably contribute to the milder ailment exerted by way of the omicron variant. The authentic Omicron variant is referred to as BA.1, due to the detection of a number of sub lineages of the variant in circulation. While the emergence of BA.1 coincided with a wave of covid-19 infections around the world due to its greater transmissibility and expanded danger of reinfection than previous variants,[Imperial college Covid-19 Response Team 2021] sub lineages BA.2 and BA.3 are also circulating, with BA.2 now accountable for an growing number of the reported cases.<sup>149</sup> The modern-day records remains limited, however, the UK Health Security Agency document that BA.2 has an expanded boom rate in contrast to BA.1 even though this document did no longer find any proof of a distinction in vaccine effective- ness between the two sub lineages of the Omicron variant.[SARS-CoV-2 Variants of Concern 2022] Indeed, the REACT-1 learn about of covid-19 transmission concluded that BA.2 had a day by day boom rate additive gain of 0.4 compared to BA.1.[Gov.uk. REACT-1 study of coronavirus transmission 2022] The chance of hospitalization does not seem to be greater for BA.2 contamination in evaluation to BA.1, however. [ Gov.uk. REACT-1 study of coronavirus transmission 2022] Emerging sub lineages of the Omicron variant will be required to be monitored and said upon for the foreseeable the future. Although the omicron variant looks to manifest in moderate disease, excessive contamination numbers should nevertheless result in high

prices of sanatorium admission and loss of life in those humans vulnerable to the virus. Omicron case numbers may want to be establishing to peak, however. In South Africa, a 29.7% reduce in weekly covid-19 infections have been stated in the week ending 25 December 2021, in contrast with the previous week, and the omicron wave is said to have passed. [Sacoronavirus.co.za. Cabinet approves changes to covid-19 regulations 2021] Concerningly, global case numbers proceed to rise rapidly [Taylor L. Covid-19: omicron drives 2022] and many nations will continue to feel the stress exerted via the wave of omicron infections.

### Variants of interest

#### *Lambda variant c.27*

The lambda variant, of the C.37 lineage, used to be first documented in Peru in December 2020 and used to be designated as a variant of activity on 14 June 2021 [ Who.int. Tracking SARSCoV-2 Variants. 2022 ].This variant includes the S protein mutations D614G, L452Q, and F490S.[ Ecdc,Europa,eu SARS-CoV-2 Variants of concern 2022] The L452Q mutation, located within the RBD, enhances binding affinity to the ACE2 receptor and will increase the infectivity of the lambda variant,[Tada T, Zhou H, et al.,2021 ]while, collectively L452Q and F490S, growing the variant's resistance to vaccine elicited antibody neutralization.[ Tada T, Zhou H, et al.,2021] Furthermore, F490S was recognized as being a excessive risk mutation for bettering skills to escape neutralization.[ Tada T, Zhou H, et al.,2021] Infectivity of the lambda variant ought to be greater than that of the alpha, gamma, and different D614G containing variants,[Acevedo ML, Alonso-Palomares L, et al.,2021] suggesting that lambda may want to spread extra swiftly and effectively. Additionally, compared with the essential SARS-CoV-2 virus,

antibody neutralization was once located to minimize by way of 3.05- fold for the lambda variant, greater than that for the gamma (2.33-fold) and alpha (2.03-fold) variants.[ Acevedo ML, Alonso-Palomares L, et al.,2021] However, findings from a preprint learn about recommend that the lambda variant can be neutralized by using monoclonal antibodies, and that cutting-edge vaccines are shielding against this variant.[ Tada T, Zhou H, et al.,2021]

#### *Mu variant B. 1, 621*

The mu variant, from the B.1.621 lineage, used to be first documented in Columbia in January 2021 before receiving designation as a variant of activity on 30 August 2021[Who.int. Tracking SARS-CoV-2 Variants. 2022.] .This variant includes the S protein mutations E484K, N501Y, D614G, and P681H.[ Ecdc,Europa,eu SARS-CoV-2 Variants of concern 2022] Mu also includes the S protein mutation R346K, located within the RBD,[ Ecdc,Europa,eu SARS-CoV2 Variants of concern 2022, Laiton-Donato K, Franco-Munoz C, et al .,2021] which can set off large, binding, free energy adjustments that disrupt the binding of antibodies to the S protein and decorate the potential of the variant to break out neutralisation.[Chen J, Gao K, et al.,2021] As discussed, the E484K, N501Y, D614G, and P681H mutations have been shown to make bigger transmissibility [Starr TN, Greaney AJ, et al., 2020, Scudellari M. How the corona virus infects cells 2021, Yurkovetskiy L, Wang X, et al., 2020, Gu H, Chen Q, et al.,2020, Sinha S, Tam B, et al.,2021, Khan A , Zia T et al.,2021, Korber B, Fischer WM,et al., 2020, Volz E, Hill V, et al.,2021] and neutralisation escape,[Collier DA, De Marco A. et al., 2021, Plante JA, Liu Y , et al., 2021] suggesting that the mu variant is possibly to be more infectious than the primary strain. Although the lambda and mu variants have been outcompeted by the delta and now omicron variants, the

improvement and spread of these variants of interest will want to be closely monitored and studied to respect their pathogenicity, transmissibility, and virulence.

### Guidelines

The treatment and management of covid-19 is a continually evolving topic; however, health authorities have published and continue to update guidelines and pointers for treating covid-19. The WHO dwelling guidelines on covid-19 and treatment id regularly updated, with the modern-day version (published on 14 January 2022) containing 14 recommendations on covid19 treatment. [Who.int. Therapeutics and COVID-19 2021] The UK National Institute for Health and Care Excellence [Nice.org.uk. COVID-19, 2021] and Medicines and Healthcare merchandise Regulatory agency [Gov. UK. MHRA guidance on coronavirus 2021] supply up to date hints on covid-19 treatment and in Europe, the ECDC normally publishes numerous tips imparting recommendations on a range of covid -19 related topics [Nih.gov. coronavirus disease 2019, 2022] The US National institutes of health [Nih.gov. coronavirus disease 2019, 2022] and centres for disease control and prevention [Cdc. Gov. guidance for COVID-19 2020] provide education on covid-19 cure and management with the centres for disease control and prevention offering guidelines for precise corporations such as employers schools, fitness departments and governments.

### Considerations for the future

Novel infectious diseases and pandemics are an unpredictable but inevitable aspect of nature; therefore, we should learn from past pandemics to prepare for future ones. Firstly, the covid19 pandemic has highlighted and amplified the existing inequalities within society,[Blundell R ,

Costa Dias M et al., 2020] with Black ethnicity, social disadvantage, and unemployment being risk factors for covid-19 infection[Chadeau-Hyam M, Bodinier B, et al., 2020] and those groups most economically deprived found to be particularly vulnerable.[Patel A, Nielsen FBH, et al., 2020] These inequalities need resolving in order for us to be better prepared for similar situations in the future. Next, to progress through a pandemic we should be racing against the pathogen, and not against each other. This statement becomes apparent when considering the problems faced by countries seeking out personal protective equipment, [Cohen J, Rodgers YvanderM et al.,2020]and the vaccine inequity seen worldwide, [Who.int. vaccine equity 2022] with developed countries often better placed to be able to purchase these items. Initiatives such as WHO's COVAX programme are vital to protect the most vulnerable groups and reduce the global spread of disease. In October 2021, the UK government released a publication outlining where the policies implemented to reduce the impact of the covid-19 pandemic failed, and the lessons learnt from these failures. [Parliament, UK. Coronavirus 2021] The publication then presents conclusions and recommendations on how to enhance pandemic preparedness, lockdown and social distancing measures, testing and contact tracing, social care, and vaccines. In countries such as the UK, US, and much of Europe, where the covid-19 death rate has been high, steps need to be taken and lessons need to be learnt in order to be better prepared for the next pandemic. The responsibility of improving pandemic response lies with policy makers, the medical/scientific community, and the public, and will ultimately require a collaborative approach. However, certain aspects of the response to the covid-19 pandemic have been a triumph. One major

victory was the rapid development and rollout of vaccines, [Ball P. The lightning-fast quest for covid vaccines 2021] which continue to be effective. The rollout of rapid testing and quarantine for infected individuals was also important to at least disrupt the spread of the virus, especially given that asymptomatic individuals can contribute to the spread. Furthermore, the swift identification and sharing of knowledge of SARS-CoV-2 variants between countries should be applauded. Lessons can be learnt from countries where covid-19 was controlled. In Taiwan, authorities managing the pandemic as directed by precovid-19 pandemic plans prompted an immediate response. Screening of all airline passengers arriving from Wuhan and high risk areas, restricting entry for non-Taiwanese citizens, 14 day quarantine periods for contacts of people with confirmed covid-19 or returning travellers, a ban on large gatherings, and widespread mask wearing were some of the quickly implemented management strategies.[Summers J, Cheng H-Y , et al., 2020]New Zealand implemented similarly effective restrictions, with the addition of a national lockdown.[ Summers J, Cheng H-Y , et al., 2020]Many of the pandemic control components that kept infection and death numbers low in Taiwan and New Zealand could be adopted by other countries in the future and could lead to improved outcomes in terms of protecting the health of individuals and the health and wellbeing of the country. Overall, much can be learnt from the covid-19 pandemic and, as we emerge from it, the inspection of which policies failed, and which succeeded is imperative.

### Conclusion

Covid-19 remains prevalent and life threatening. Although the rollout of vaccines has been successful, attaining a

high global vaccination coverage and ensuring that all healthcare systems have the capacity to cope with seasonal waves are essential. With the omicron variant highly prevalent, we must continue to learn, develop therapeutics, and remain vigilant to new variants of concern. Here, we have provided an overview of the virology of SARS-CoV-2, including the mutations harboured by variants of the virus and how these mutations effect its transmissibility and virulence. We have also discussed the vaccines that have been developed and used around the world and have provided evidence supporting the rollout of booster doses. Future priorities should focus on continuing vaccination programmes and developing variant specific vaccines as new mutations emerge. This strategy, along with the expansion of our knowledge of SARS-CoV-2 and which treatments are most successful to treat covid-19 infections will ultimately lead to favourable outcomes.

### Acknowledgement

The authors are grateful to Department of Microbiology, University of Kota, Kota for providing this opportunity.

### References

1. CDC.org. Human coronavirus types. centres for disease control and prevention. Available: <https://www.cdc.gov/coronavirus/types.html> [Accessed 15 February 2020]. Prevention. Available: <https://www.cdc.gov/coronavirus/types.html>. [Accessed 15 February 2020].
2. Who.int. Weekly operational update on COVID-19 - 25 January

2022. World Health Organization. Available: <https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19-25-january-2022> [Accessed 25 January 2022].
3. Who.int. Tracking SARS-CoV-2 variants. World health organization. Available: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>[Accessed 25 January 2022].
  4. [Covid19.trackvaccines.org](https://covid19.trackvaccines.org). COVID-19 vaccine Tracker. Available: <https://covid19.trackvaccines.org/>. [Accessed 24 January 2022].
  5. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*.2020;395:514–23. doi:10.1016/S0140-6736(20)30154-9
  6. Who.int. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific Brief. World Health Organization. Available: <https://www.who.int/newsroom/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions> [Accessed 9 July 2020].
  7. Gidari A, Sabbatini S, Bastianelli S, et al. SARS-CoV-2 survival on surfaces and the effect of UV-C light. *Viruses* 2021;13. doi:10.3390/v13030408. [Epub ahead of print: 05 03 2021].
  8. Pottage T, Garratt I, Onianwa O, et al. A comparison of persistence of SARS-CoV-2 variants on stainless steel. *J Hosp Infect* 2021; 114:163–6. doi: 10.1016/j.jhin.2021.05.015
  9. Guo L, Wang M, Zhang L, et al. Transmission risk of viruses in large mucosalivary droplets on the surface of objects: a time-based analysis. *Infect Dis Now* 2021; 51:219–27. doi: 10.1016/j.idnow.2020.11.001
  10. Carraturo F, Del Giudice C, Morelli M, et al. Persistence of SARS-CoV-2 in the environment and COVID-19 transmission risk from environmental matrices and surfaces. *Environ Pollut*2020; 265:115010. doi: 10.1016/j.envpol.2020.115010.
  11. Hui KPY, Cheung M-C, Perera RAPM, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in *ex-vivo* and *in-vitro* cultures. *Lancet Respir Med* 2020; 8:687–95. doi:10.1016/S22132600(20)30193-4.
  12. McAloon C, Collins Áine, Hunt K, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. *BMJ Open* 2020;10: e039652. doi:10.1136/bmjopen-2020-039652
  13. Bliddal S, Banasik K, Pedersen OB, et al. Acute and persistent symptoms in nonhospitalized PCR-confirmed COVID-19

- patients. *Sci Rep* 2021; 11:13153. doi:10.1038/s41598-021-92045-x.
14. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and metaanalysis of 148 studies from 9 countries. *PLoS One* 2020;15: e0234765. doi: 10.1371/journal.pone.0234765.
  15. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. *Int J Infect Dis* 2020; 98:180–6. doi: 10.1016/j.ijid.2020.06.052.
  16. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections, and transmission in a skilled nursing facility. *N Engl J Med* 2020; 382:2081–90. doi:10.1056/NEJMoa2008457.
  17. Cao Y, Wang J, Jian F. B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. *BioRxiv* 2021. doi:10.1101/2021.12.07.470392.
  18. Wolff D, Nee S, Hickey NS, et al. Risk factors for Covid-19 severity and fatality: a structured literature review. *Infection* 2021; 49:15–28. doi:10.1007/s15010-020-01509-1.
  19. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395:1054–62. doi:10.1016/S0140-6736(20)30566-3.
  20. Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect* 2020; 26:767–72. doi: 10.1016/j.cmi.2020.04.012.
  21. Ebinger JE, Achamallah N, Ji H, et al. Pre-Existing traits associated with Covid-19 illness severity. *PLoS One* 2020;15: e0236240. doi: 10.1371/journal.pone.0236240.
  22. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; 584:430–6. doi:10.1038/s41586-020-2521-4.
  23. Li R, Tian J, Yang F, et al. Clinical characteristics of 225 patients with COVID-19 in a tertiary hospital near Wuhan, China. *J Clin Virol* 2020; 127:104363. doi: 10.1016/j.jcv.2020.104363.
  24. Guo L, Shi Z, Zhang Y, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis. *Diabetes Res Clin Pract* 2020; 166:108346. doi: 10.1016/j.diabres.2020.108346.
  25. Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. *Am J Respir Crit Care Med* 2020; 201:1380–8. doi:10.1164/rccm.2020020445OC.
  26. Tian J, Yuan X, Xiao J, et al. Clinical characteristics, and risk



- factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicenter, retrospective, cohort study. *Lancet Oncol* 2020; 21:893–903. doi:10.1016/S1470-2045(20)30309-0.
27. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020; 21:335–7. doi:10.1016/S1470-2045(20)30096-6.
28. Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. *Lancet HIV* 2020;7: e554–64. doi:10.1016/S2352-3018(20)30164-8.
29. Baillie JK, Wilson JF, Bulteel N. Mapping the human genetic architecture of COVID-19. *Nature* 2021. doi:10.1038/s41586-021-03767-x.
30. Shelton JF, Shastri AJ, Ye C. Trans-Ethnic analysis reveals genetic and non-genetic associations with COVID-19 susceptibility and severity. *MedRxiv* 2020. doi:10.1038/s41588021-00854-7.
31. Ellinghaus D, Degenhardt F, et al, Severe Covid-19 GWAS Group. Genome wide association study of severe Covid-19 with respiratory failure. *N Engl J Med* 2020; 383:1522-1534. doi:10.1056/NEJMoa2020283.
32. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020;181: e8:271–80. doi:10.1016/j.cell.2020.02.052.
33. Hou Y, Zhao J, Martin W, et al. new insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. *BMC Med* 2020; 18:1–8. doi:10.1186/s12916020-01673-z.
34. Barbry P, Muus C, Luecken M. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV2 viral entry and highlights inflammatory programs in putative target cells. *BioRxiv* 2020. doi:10.1101/2020.04.19.049254.
35. Prakrithi P, Lakra P, Sundar D, et al. Genetic risk prediction of COVID-19 susceptibility and severity in the Indian population. *Front Genet* 2021; 12:714185. doi:10.3389/fgene.2021.714185.
36. Huang Q-M, Zhang P-D, Li Z-H, et al. Genetic risk, and chronic obstructive pulmonary disease independently predict the risk of incident severe COVID-19. *Ann Am Thorac Soc* 2022; 19:58–65. doi:10.1513/AnnalsATS.202102-1710C.
37. Zhou Y, Qian X, Liu Z, et al. Coagulation factors and the incidence of COVID-19 severity: Mendelian randomization analyses and supporting evidence. *Signal Transduct Target Ther* 2021; 6:222.
38. Masters PS, Kuo L, Ye R, et al. Genetic and molecular biological

- analysis of protein-protein interactions in coronavirus assembly. *Adv Exp Med Biol* 2006; 581:163–73. doi:10.1007/9780-387-33012-9\_29.
39. Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. *Gene Rep* 2020; 19:100682. doi:10.1016/j.genrep.2020.100682.
40. Thoms M, Buschauer R, Ameismeier M, et al. Structural basis for translational shutdown and immune evasion by the nsp1 protein of SARS-CoV-2. *Science* 2020; 369:1249–55. doi:10.1126/science.abc8665.
41. Schubert K, Karousis ED, Jomaa A, et al. SARS-CoV-2 nsp1 binds the ribosomal mRNA channel to inhibit translation. *Nat Struct Mol Biol* 2020; 27:959–66. doi:10.1038/s41594-0200511-8.
42. Huang C, Lokugamage KG, Rozovics JM, et al. Sars coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. *PLoS Pathog* 2011;7:e1002433. doi:10.1371/journal.ppat.1002433.
43. Snijder EJ, Decroly E, Ziebuhr J. The nonstructural proteins directing coronavirus RNA synthesis and processing. *Adv Virus Res* 2016; 96:59–126. doi:10.1016/bs.aivir.2016.08.008.
44. V'kovski P, Gerber M, Kelly J, et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. *Elife* 2019;8. doi:10.7554/eLife.42037. [Epub ahead of print: 11 01 2019].
45. Masters PS. The molecular biology of coronaviruses. *Adv Virus Res* 2006; 66:193–292. doi:10.1016/S0065-3527(06)66005-3.
46. Siu YL, Teoh KT, Lo J, et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. *J Virol* 2008; 82:11318–30. doi:10.1128/JVI.01052-08.
47. Kuo L, Masters PS. Genetic evidence for a structural interaction between the carboxy termini of the membrane and nucleocapsid proteins of mouse hepatitis virus. *J Virol* 2002; 76:4987–99. doi:10.1128/jvi.76.10.4987-4999.2002.
48. Hulswit RJG, de Haan CAM, Bosch B-J. Coronavirus spike protein and tropism changes. *Adv Virus Res* 2016; 96:29–57. doi:10.1016/bs.aivir.2016.08.004.
49. Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. *Cell Rep* 2020; 32:108185. doi:10.1016/j.celrep.2020.108185.
50. Kopecky-Bromberg SA, Martínez-Sobrido L, Frieman M, et al. severe acute respiratory syndrome coronavirus open

- reading frame (ORF) 3B, ORF 6, and nucleocapsid proteins function as interferon antagonists. *J Virol* 2007; 81:548–57. doi:10.1128/JVI.01782-06.
51. Xia H, Cao Z, Xie X, et al. Evasion of type I interferon by SARS-CoV-2. *Cell Rep* 2020; 33:108234. doi: 10.1016/j.celrep.2020.108234.
  52. Wong HH, Fung TS, Fang S, et al. Accessory proteins 8B and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. *Virology* 2018; 515:165–75. doi: 10.1016/j.virol.2017.12.028.
  53. Azad GK, Khan PK. Variations in Orf3a protein of SARS-CoV-2 alter its structure and function. *Biochem Biophys Rep* 2021; 26:100933. doi: 10.1016/j.bbrep.2021.100933.
  54. Ren Y, Shu T, Wu D, et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. *Cell Mol Immunol* 2020; 17:881–3. doi:10.1038/s41423-020-0485-9.
  55. Kreimendahl S, Rassow J. The mitochondrial outer membrane protein Tom70-Mediator in protein traffic, membrane contact sites and innate immunity. *Int J Mol Sci* 2020;21. doi:10.3390/ijms21197262. [Epub ahead of print: 01 Oct 2020].
  56. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 2020; 583:459–68. doi:10.1038/s41586-020-2286-9.
  57. Dominguez Andres A, Feng Y, Campos AR, et al. SARS-CoV-2 ORF9c is a membrane associated protein that suppresses antiviral responses in cells. *bioRxiv* 2020. doi:10.1101/2020.08.18.256776. [Epub ahead of print: 19 Aug 2020].
  58. Redondo N, Zaldívar-López S, Garrido JJ, et al. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. *Front Immunol.* 2021; 12:708264. doi:10.3389/fimmu.2021.708264.
  59. Bosch BJ, van der Zee R, de Haan CAM, et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. *J Virol.* 2003; 77:8801–11. doi:10.1128/jvi.77.16.8801-8811.2003.
  60. Li F. Structure, function, and evolution of coronavirus spike proteins. *Annu Rev Virol* 2016; 3:237–61. doi:10.1146/annurev-virology-110615-042301.
  61. Wrapp D, Wang N, Corbett KS, et al. Cryo-Em structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020; 367:1260–3. doi:10.1126/science.abb2507.
  62. Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 2020; 181:281–92. doi: 10.1016/j.cell.2020.02.058.
  63. Khare S, Azevedo M, Parajuli P, et al. Conformational changes of

- the receptor binding domain of SARS-CoV-2 spike protein and prediction of a B-cell antigenic epitope using structural data. *Front Artif Intell* 2021; 4:630955. doi:10.3389/frai.2021.630955.
64. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020; 581:215–20. doi:10.1038/s41586-020-2180-5.
65. Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. *Virus Res* 2015; 202:120–34. doi: 10.1016/j.virusres.2014.11.021.
66. Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004; 203:631–7. doi:10.1002/path.1570.
67. Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J Virol* 2011; 85:4122–34. doi:10.1128/JVI.02232-10.
68. Zhao M-M, Yang W-L, Yang F-Y, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. *Signal Transduct Target Ther* 2021; 6:134. doi:10.1038/s41392-021-00558-8.
69. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020; 181:271–80. doi: 10.1016/j.cell.2020.02.052.
70. Duchene S, Featherstone L, Haritopoulou-Sinanidou M, et al. Temporal signal and the phylodynamic threshold of SARS-CoV-2. *Virus Evol* 2020; 6: veaa061. doi:10.1093/ve/veaa061.
71. Ecdc.europa.eu. Methods for the detection and characterization of SARS-CoV-2 variants - first update. European Centre for Disease Prevention and Control. Available: <https://www.ecdc.europa.eu/en/publications-data/methods-detection-and-characterisation-sars-cov-2-variants-first-update> [Accessed 20 December 2021].
72. Cdc.gov. COVID-19: about variants. centers for disease control and prevention. Available: <https://www.cdc.gov/coronavirus/2019-ncov/variants/about-variants.html> [Accessed 13 December 2021].
73. Imperial.ac.uk. Report 50 - Hospitalisation risk for Omicron cases in England. Imperial College London, MRC Centre for Global Infectious Disease Analysis. Available: <https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron/>. [Accessed 22 December 2021].

74. Gov.uk. SARS-CoV-2 variants of concern and variants under investigation in England - Technical briefing 33. UK Health Security Agency. Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1043807/technical-briefing-33.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043807/technical-briefing-33.pdf) [Accessed 23 December 2021].
75. Luna-Muschi A, Borges IC, de Faria E, et al. Clinical features of COVID-19 by SARSCoV-2 gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers. *J Infect* 2022; 84:248-288. doi: 10.1016/j.jinf.2021.09.005.
76. Gov.uk. Investigation of novel SARS-CoV-2 variant - Variant of Concern 202012/01 - Technical briefing 5. UK Health Security Agency (formerly Public Health England). Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/959426/Variant\\_of\\_Concern\\_VOC\\_202012\\_01\\_Technical\\_Briefing\\_5.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf) [Accessed 14 January 2021].
77. Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. *Proc Natl Acad Sci U S A* 2020; 117:13967–74. doi:10.1073/pnas.2008209117.
78. Yi C, Sun X, Ye J, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. *Cell Mol Immunol* 2020; 17:621–30. doi:10.1038/s41423-020-0458-z.
79. Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. *Cell* 2020;182: e20:1295–310. doi: 10.1016/j.cell.2020.08.012.
80. Huang Y, Yang C, Xu X-F, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta Pharmacol Sin* 2020; 41:1141–9. doi:10.1038/s41401-020-0485-4.
81. Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. *Mol Cell* 2020; 78:779–84. doi:10.1016/j.molcel.2020.04.022.
82. Peacock TP, Goldhill DH, Zhou J. The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells. *BioRxiv* 2020. doi:10.1038/s41564-021-00908-w.
83. Zhu Y, Feng F, Hu G. The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. *BioRxiv*2020. doi:10.1101/2020.08.25.266775.
84. Scudellari M. How the coronavirus infects cells - and why Delta is so dangerous. *Nature* 2021; 595:640–4. doi:10.1038/d41586-021-02039-y.

85. Wang Q, Qiu Y, Li J-Y, et al. A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility. *Virol Sin* 2020; 35:337–9. doi:10.1007/s12250-020-00212-7.
86. Yurkovetskiy L, Wang X, Pascal KE, et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. *Cell* 2020; 183:739–51. doi: 10.1016/j.cell.2020.09.032.
87. McCarthy KR, Rennick LJ, Nambulli S. Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. *BioRxiv* 2021. doi:10.1101/2020.11.19.389916.
88. Kemp SA, Collier DA, Datir R, et al. Neutralising antibodies in spike mediated SARS-CoV2 adaptation. *medRxiv* 2020. doi:10.1101/2020.12.05.20241927 . [Epub ahead of print: 29 Dec 2020].
89. Gamage AM, Tan KS, Chan WOY, et al. Infection of human nasal epithelial cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. *PLoS Pathog* 2020;16: e1009130. doi: 10.1371/journal.ppat.1009130.
90. Collier DA, De Marco A, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature* 2021; 593:136–41. doi:10.1038/s41586-021-034127.
91. Martínez-García L, Espinel MA, Abreu M, et al. Emergence and spread of B.1.1.7 lineage in primary care and clinical impact in the Morbi-Mortality among hospitalized patients in Madrid, Spain. *Microorganisms* 2021; 9:1517. doi:10.3390/microorganisms9071517.
92. Vassallo M, Manni S, Klotz C, et al. Patients admitted for variant alpha COVID-19 have poorer outcomes than those infected with the old strain. *J Clin Med* 2021;10. doi:10.3390/jcm10163550. [Epub ahead of print: 12 08 2021].
93. McAlister FA, Nabipour M, Chu A. Lessons from the COVID-19 third wave in Canada: the impact of variants of concern and shifting demographics. *MedRxiv* 2021. doi:10.1101/2021.08.27.21261857 .
94. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility, and impact of SARSCoV-2 lineage B.1.1.7 in England. *Science* 2021;372. doi:10.1126/science. abg3055.
95. Leung K, Shum MH, Leung GM, et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. *Euro Surveill* 2021;26. doi:10.2807/1560-7917.ES.2020.26.1.2002106.
96. Zhao S, Lou J, Cao L, et al. Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: an early data-driven analysis. *J Travel Med* 2021;28.

- doi:10.1093/jtm/taab011. [Epub ahead of print: 23 02 2021].
97. Gov.uk. NERVTAG paper on COVID-19 variant of concern B.1.1.7. NERVTAG COVID-19. Public statements. Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/961037/NERVTAG\\_note\\_on\\_B.1.1.7\\_severity\\_for\\_SAGE\\_77\\_1\\_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961037/NERVTAG_note_on_B.1.1.7_severity_for_SAGE_77_1_.pdf) [Accessed 22 January 2021].
  98. Challen R, Brooks-Pollock E, Read JM, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* 2021;372: n579. doi:10.1136/bmj.n579.
  99. Paredes MI, Lunn SM, Famulare M, et al. Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington state: a retrospective cohort study. *medRxiv* 2022. doi:10.1101/2021.09.29.21264272 . [Epub ahead of print: 16 Feb 2022].
  100. Wang P, Nair MS, Liu L. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *BioRxiv* 2021. doi:10.1101/2021.01.25.428137.
  101. Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *bioRxiv* 2021. doi:10.1101/2021.01.25.427948. [Epub ahead of print: 25 Jan 2021].
  102. Gallais F, Gantner P, Bruel T. Anti-SARS-CoV-2 antibodies persist for up to 13 months and reduce risk of reinfection. *MedRxiv* 2021. doi:10.1101/2021.05.07.21256823 .
  103. Ecdc.europa.eu. SARS-CoV-2 variants of concern as of 20 January 2022. European centre for disease prevention and control. Available: <https://www.ecdc.europa.eu/en/covid19/variants-concern> . [Accessed 20 January 2022].
  104. Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science* 2020; 369:1603–7. doi:10.1126/science.abc4730.
  105. Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* 2021; 592:116–21. doi:10.1038/s41586-020-2895-3.
  106. Pearson CA, Russell TW, Davies NG. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2. centre for mathematical modelling of infectious diseases. *CMMID Repository*, 2021.
  107. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *Nat Med* 2021; 27:622–5. doi:10.1038/s41591-02101285-x.
  108. Sinha S, Tam B, Wang SM. Altered interaction between RBD and ACE2 receptor contributes towards the increased transmissibility of SARS CoV-2 delta, kappa, beta, and gamma

- strains with RBD double mutations. *BioRxiv* 2021. doi:10.1101/2021.08.30.458303.
109. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility, and global spread of SARS-CoV-2 variants of concern as of June 2021. *Euro Surveill* 2021;26. doi:10.2807/1560-7917.ES.2021.26.24.2100509.
  110. Ecdc.europa.eu. Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update. European Centre for Disease Prevention and Control. Available: <https://www.ecdc.europa.eu/en/publications-data/covid.19-risk-assessment-variants-vaccine-fourteenth-update-february-2021> [Accessed 15 February 2021].
  111. Khan A, Zia T, Suleman M, et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data. *J Cell Physiol* 2021; 236:7045–57. doi:10.1002/jcp.30367.
  112. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science* 2020; 369:1014–8. doi:10.1126/science. abd0831.
  113. Curran J, Dol J, Boulos L. Transmission characteristics of SARS-CoV-2 variants of concern. *MedRxiv* 2021. doi:10.1101/2021.04.23.21255515 .
  114. de Faria E, Guedes AR, Oliveira MS. Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report. *MedRxiv* 2021. doi:10.1101/2021.04.12.21255308 .
  115. Freitas ARR, Beckedorff OA, Cavalcanti LPdeG, et al. The emergence of novel SARSCoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: a population based ecological study. *Lancet Reg Health Am* 2021; 1:100021. doi: 10.1016/j.lana.2021.100021.
  116. Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. *Euro Surveill* 2021;26. doi:10.2807/1560-7917.ES.2021.26.16.2100348.
  117. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet*2021; 397:452–5. doi:10.1016/S0140-6736(21)00183-5.
  118. Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS CoV-2. *Cell* 2021; 184:2939–54. doi: 10.1016/j.cell.2021.03.055.
  119. Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike evidence that D614G increases infectivity of the COVID-19



- virus. *Cell* 2020;182: e19:812–27. doi:10.1016/j.cell.2020.06.043.
120. Volz E, Hill V, McCrone JT, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. *Cell* 2021; 184: e11:64–75. doi: 10.1016/j.cell.2020.11.020.
  121. Augusto G, Mohsen MO, Zinkhan S. *In vitro* data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. *Allergy* 2021;77. doi:10.1111/all.15065.
  122. Tchesnokova V, Kulakesara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of spike protein triggers recent massive expansion of SARS-Cov-2 variants. *bioRxiv*2021. doi:10.1128/JCM.00921-21. [Epub ahead of print: 11 Mar 2021].
  123. Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. *Cell* 2020; 182:1284–94. doi: 10.1016/j.cell.2020.07.012.
  124. Di Giacomo S, Mercatelli D, Rakhimov A, et al. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike mutation T478K. *J Med Virol* 2021;93:5638–43. doi:10.1002/jmv.27062.
  125. Torjesen I. Covid-19: delta variant is now UK's most dominant strain and spreading through schools. *BMJ* 2021;373: n1445. doi:10.1136/bmj.n1445.
  126. Reuters.com. Delta COVID variant now dominant strain worldwide, U.S. deaths surge officials. O'donnell C, Mason J, Reuters. Available: [www.reuters.com](http://www.reuters.com) [Accessed 16 July 2021].
  127. Euro.who.int. SARS-CoV-2 delta variant now dominant in much of European region; efforts must be reinforced to prevent transmission, warns who regional office for Europe and ECDC. World health organization. Available: <https://www.euro.who.int/en/mediacentre/sections/press-releases/2021/sars-cov-2-delta-variant.now-dominant-in-much-of-european-region-efforts-must-be-reinforced-to-prevent-transmission,warns-who-regional-office-for-europe-and-ecdc> [Accessed 23 July 2021].
  128. Li B, Deng A, Li K. Viral infection, and transmission in a large well-traced outbreak caused by the SARS-CoV-2 delta variant. *MedRxiv* 2021. doi:10.1101/2021.07.07.21260122 .
  129. Teyssou E, Delagrèverie H, Visseaux B, et al. The delta SARS-CoV-2 variant has a higher viral load than the beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. *J Infect* 2021; 83: e1–3. doi: 10.1016/j.jinf.2021.08.027.
  130. Kumar A, Asghar A, Raza K. Demographic characteristics of

- SARS-CoV-2 B.1.617.2 (delta) variant infections in Indian population. MedRxiv 2021. doi:10.1101/2021.09.23.21263948
131. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. *Nature* 2021; 596:276–80. doi:10.1038/s41586-021-03777-9.
132. Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* 2021; 397:2461–2. doi:10.1016/S0140-6736(21)01358-1.
133. Fisman DN, Tuite AR. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada. MedRxiv 2021. doi:10.1101/2021.07.05.21260050
134. Cameroni E, Saliba C, Bowen JE. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. *BioRxiv* 2021. doi:10.1101/2021.12.12.472269.
135. Shah M, Woo HG. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes Approved COVID-19 therapeutic antibodies. *Front Immunol* 2021; 12:830527. doi:10.3389/fimmu.2021.830527.
136. Wolter N, Jassat W, Walaza S. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa. *MedRxiv* 2021. doi:10.1101/2021.12.21.21268116
137. Gov.uk. Omicron daily overview: 24 December 2021. UK health security agency. Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1043866/20211224\\_OS\\_Daily\\_Omicron\\_Overview.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043866/20211224_OS_Daily_Omicron_Overview.pdf) [Accessed 24 December 2021].
138. Who.int. Enhancing readiness for omicron (B.1.1.529): technical brief and priority actions for member states. World health organization. Available: [https://www.who.int/docs/default-source/coronaviruse/2021-12-23-global-technical-brief-and-priority-action-on-omicron.pdf?sfvrsn=d0e9fb6c\\_8](https://www.who.int/docs/default-source/coronaviruse/2021-12-23-global-technical-brief-and-priority-action-on-omicron.pdf?sfvrsn=d0e9fb6c_8) [Accessed 23 December 2021].
139. Med.hku.hk. HKUMed finds omicron SARS-CoV-2 can infect faster and better than delta in human bronchus but with less severe infection in lung. The University of Hong Kong, LKS faculty of medicine. Available: <https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2infection> [Accessed 15 December 2021].
140. Sheikh A, Kerr S, Woolhouse M. Severity of omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland; 2021.
141. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection

- associated with emergence of omicron in South Africa. *Science* 2022; eabn4947. doi:10.1126/science. Abn 4947.
142. Cele S, Jackson L, Khoury DS, et al. SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. *medRxiv* 2021. doi:10.1101/2021.12.08.21267417. [Epub ahead of print: 17 Dec 2021].
143. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. *Nature* 2022; 602:671–5. doi:10.1038/s41586-021-04389-z.
144. Meng B, IATM F, Abdullahi A. SARS-CoV-2 omicron spike mediated immune escape, infectivity, and cell-cell fusion. *BioRxiv* 2021. doi:10.1101/2021.12.17.473248.
145. Pfizer.com. Pfizer and BioNTech provide update on omicron variant. Pfizer. Available: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-andbiontech-provide-update-omicron-variant> [Accessed 8 December 2021].
146. Keeton R, Tincho MB, Ngomti A. SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against omicron. *MedRxiv* 2021. doi:10.1101/2021.12.26.21268380.
147. Imperial College Covid-19 Response Team. Report 49: growth, population distribution and immune escape of omicron in England, 2021. Available: <https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-1216-COVID19-Report-49.pdf>.
148. BA.2 lineage report. Outbreak.info. Available: <https://outbreak.info/situation-reports?pango=BA.2>.
149. SARS-CoV-2 variants of concern and variants under investigation in England. technical briefing 35, 2022. Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1050999/Technical-Briefing-35-28January2022.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022.pdf) [Accessed 28 Jan 2022].
150. Gov.uk. REACT-1 study of coronavirus transmission: February 2022 final results, 2022. Available: <https://www.gov.uk/government/publications/react-1-study-of-coronavirus-transmission-february-2022-final-results/react-1-study-of-coronavirus-transmission-february-2022-final-results> [Accessed 10 Mar 2022].
151. Gov.uk. SARS-CoV-2 variants of concern and variants under investigation in England - Technical briefing 38, 2022. Available: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1060337/Technical-Briefing-38-](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1060337/Technical-Briefing-38-)

- 11March2022.pdf [Accessed 11 Mar 2022].
152. Sacoronavirus.co.za. Cabinet approves changes to covid-19 regulations. South Africa department of health. Available: <https://sacoronavirus.co.za/2021/12/30/media-releasecabinet-approves-changes-to-covid-19-regulations/> [Accessed 30 December 2021].
153. Taylor L. Covid-19: omicron drives Weekly record high in global infections. *BMJ* 2022; 376: o66. doi:10.1136/bmj. o66.
154. Tada T, Zhou H, Dcosta BM. SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum. *BioRxiv* 2021. doi:10.1101/2021.07.02.450959.
155. Acevedo ML, Alonso-Palomares L, Bustamante A. Infectivity, and immune escape of the new SARS-CoV-2 variant of interest lambda. *MedRxiv* 2021. doi:10.1101/2021.06.28.21259673 .
156. Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. *Infect Genet Evol* 2021; 95:105038. doi: 10.1016/j.meegid.2021.105038.
157. Chen J, Gao K, Wang R, et al. Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. *J Mol Biol* 2021; 433:167155. doi: 10.1016/j.jmb.2021.167155.
158. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. *Immunity* 2020; 52:583–9. doi: 10.1016/j.immuni.2020.03.007.
159. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020; 383:2603–15. doi:10.1056/NEJMoa2034577.
160. Who.int. Therapeutics and COVID-19: living guideline. World health organisation. Available: <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.1> [Accessed 14 January 2022].
161. Nice.org.uk. COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191].
162. National Institute for Health and Care Excellence. Available: <https://www.nice.org.uk/guidance/ng191> [Accessed 16 December 2021].
163. Gov.uk. MHRA guidance on coronavirus (COVID-19). medicines and healthcare products regulatory agency. Available: <https://www.gov.uk/government/collections/mhraguidance-on-coronavirus-covid-19> [Accessed 16 September 2021].
164. Ecdc.europa.eu. All resources on COVID-19 – guidance and technical reports, 2022. Available: <https://www.ecdc.europa.eu/en/covid-19/all-reports-covid-19> [Accessed 21 January 2022].
165. Nih.gov. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of health. Available: <https://www.covid19treatmentgui>

- delines.nih.gov/ [Accessed 19 January 2022].
166. Cdc.gov. Guidance for COVID-19. centers for disease control and prevention. Available: <https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html> [Accessed 15 March 2021].
167. Blundell R, Costa Dias M, Joyce R. COVID-19 and inequalities. *Fisc Stud* 2020. doi:10.1111/1475-5890.12232.
168. Chadeau-Hyam M, Bodinier B, Elliott J, et al. Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK Biobank data. *Int J Epidemiol* 2020; 49:1454–67. doi:10.1093/ije/dyaa134.
169. Patel JA, Nielsen FBH, Badiani AA, et al. Poverty, inequality, and COVID-19: the forgotten vulnerable. *Public Health* 2020; 183:110–1. doi: 10.1016/j.puhe.2020.05.006.
170. Cohen J, Rodgers YvanderM. Contributing factors to personal protective equipment shortages during the COVID-19 pandemic. *Prev Med* 2020; 141:106263. doi: 10.1016/j.ypmed.2020.106263.
171. Who.int. Vaccine equity. World health organization. Available: <https://www.who.int/campaigns/vaccine-equity> [Accessed 10 January 2022].
172. Parliament.uk. Coronavirus: lessons learned to date. The house of commons, science and technology Committee, and health and social care Committee. Available: <https://publications.parliament.uk/pa/cm5802/cmslect/cmsctech/92/9203.html>. [Accessed 12 October 2021].
173. Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. *Nature* 2021; 589:16–18. doi:10.1038/d41586-020-03626-1.
174. Summers J, Cheng H-Y, Lin H-H, et al. Potential lessons from the Taiwan and New Zealand health responses to the COVID-19 pandemic. *Lancet Reg Health West Pac*. 2020; 4:100044. doi: 10.1016/j.lanwpc.2020.100044.